P370: EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE

P370: EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE

Bibliographic Details
Main Authors:	Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Jin Wang, Jian‑qing MI
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968392.21249.a8

Similar Items

P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL
by: Weiyang Liu, et al.
Published: (2023-08-01)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
by: Mathias Schneeweiss-Gleixner, et al.
Published: (2019-12-01)

A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
by: Honglan Qian, et al.
Published: (2022-12-01)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
by: Khateb Mamduh, et al.
Published: (2012-11-01)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021-05-01)

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
by: Jianghua Ding, et al.
Published: (2023-11-01)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
by: Michele Massimino, et al.
Published: (2021-06-01)

Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
by: Mardziah M,, et al.
Published: (2019)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
by: Saskia Maletzke, et al.
Published: (2022-01-01)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Deborah Cardinali, et al.
Published: (2023-08-01)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
by: Groffen John, et al.
Published: (2007-10-01)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
by: Congying Gao, et al.
Published: (2023-04-01)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022-03-01)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
by: Vicki Xie, et al.
Published: (2018-02-01)

Cup‐like blasts in an adult patient with BCR‐ABL1 positive B‐cell acute lymphoblastic leukemia
by: Zhenni Wang, et al.
Published: (2022-08-01)

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
by: Caterina De Benedittis, et al.
Published: (2017-08-01)

Case report: BCR-ABL-positive acute lymphoblastic leukemia with bone destruction: a treatment dilemma
by: Shi Lijun, et al.
Published: (2024-02-01)

Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart
by: Hanna Kirchhoff, et al.
Published: (2022-02-01)

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
by: Rima Koka, et al.
Published: (2017-10-01)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity
by: Kathrin Rothfelder, et al.
Published: (2018-11-01)

Papel da P190 BCR-ABL como parâmetro de recaída na leucemia mielóide crônica P190 BCR-ABL role in myeloid chronic leukemia relapse
by: Gabriela V. Andrade
Published: (2008-08-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

P394: FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Kaibo Zhu, et al.
Published: (2023-08-01)

P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.
by: Chethan R, et al.
Published: (2023-08-01)

Amplification of the BCR: : ABL1 Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia
by: Debadrita Ray, et al.
Published: (2023-08-01)

No association between BCR-ABL1 fusion genes and clinical features of acute lymphoblastic leukaemia in Ghanaian patients
by: Victor Obeng Ofori, et al.
Published: (2020-10-01)

An In-house Method for Molecular Monitoring of BCR-ABL
by: Hakkı Ogun Sercan, et al.
Published: (2012-12-01)

No Benefit of BCR-ABL1 Screening in Polycythemia
by: STEPHEN E. LANGABEER
Published: (2016-07-01)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01)

P100: BCR/ABL1 p230 transcript in B-lymphoblastic leukemia/lymphoma: A case report
by: Agshin Taghiyev, et al.
Published: (2024-01-01)

In <i>BCR-ABL1</i> Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
by: Elisa Buzzatti, et al.
Published: (2022-03-01)

BCR-ABL1-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report
by: Shuang Fu, et al.
Published: (2023-06-01)

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
by: Ilana de França Azevedo, et al.
Published: (2014-10-01)

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
by: Berke, Z, et al.
Published: (2000)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
by: Hao Zhang, et al.
Published: (2020-06-01)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
by: Baum Karina J, et al.
Published: (2008-06-01)